Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies

Search results

Showing results for

DNA prime and peptide boost immunization elicits robust neoantigen-specific CD8 + T cell responses and therapeutic protection in mouse tumor models.

Journal article

Morgado-Cáceres P. et al, (2026), Oncoimmunology, 15

Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS-chemokine-myeloid axis.

Journal article

Beernaert B. et al, (2026), Science advances, 12

Correction: Grant et al. Low pH, High Stakes: A Narrative Review Exploring the Acid-Sensing GPR65 Pathway as a Novel Approach in Renal Cell Carcinoma. Cancers 2025, 17, 3883

Journal article

Grant M. et al, (2026), Cancers, 18, 760 - 760

Tumor-targeted 4-1BB costimulation enhances immune activation and clinical activity of a CEA-directed T-cell engager in microsatellite-stable colorectal cancer

Preprint

Boehnke A. et al, (2026)

Supplementary Table 1 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors

Other

Melero I. et al, (2026)

Supplementary Figure 3 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors

Other

Melero I. et al, (2026)

Supplementary Methods 1 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors

Other

Melero I. et al, (2026)

Figure S8 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors

Other

Melero I. et al, (2026)

Supplementary Figure 1 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors

Other

Melero I. et al, (2026)

Supplementary Figure 7 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors

Other

Melero I. et al, (2026)

Data from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors

Other

Melero I. et al, (2026)

Figure S9 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors

Other

Melero I. et al, (2026)

Supplementary Figure 5 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors

Other

Melero I. et al, (2026)

Supplementary Figure 6 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors

Other

Melero I. et al, (2026)

Supplementary Figure 4 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors

Other

Melero I. et al, (2026)

Supplementary Figure 2 from Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen–Positive Advanced/Metastatic Solid Tumors

Other

Melero I. et al, (2026)

Facts and Hopes in Harnessing Macrophage-Mediated Antibody-Dependent Cellular Phagocytosis for Cancer Immunotherapy.

Journal article

Armero M. et al, (2026), Clinical cancer research : an official journal of the American Association for Cancer Research, 32, 455 - 464

Response to Comments on 'Hepatitis B Virus (HBV) Treatment Eligibility in the UK: Retrospective Longitudinal Cohort Data to Explore the Impact of Changes in Clinical Guidelines'.

Journal article

Campbell C. et al, (2026), Journal of viral hepatitis, 33

Comprehensive Spatial Methods (CSM): a Toolbox for Spatially Analyzing Tissues in Histopathology.

Journal article

Lopez-Janeiro A. et al, (2026), Laboratory investigation; a journal of technical methods and pathology, 106

Unsuppressed viraemia and lower CD4 count associated with faster telomere attrition in African children with perinatal HIV on long-term antiretroviral therapy.

Journal article

Shellard JPG. et al, (2026), The Journal of infectious diseases

Load More